Acelrx pharmaceuticals announces the european launch of dzuveo by its partner, aguettant

Physicians across europe will now have access to dzuveo®, a novel sublingual approach to acute pain management in medically supervised settings hayward, calif. , oct. 27, 2022 /prnewswire/ -- acelrx pharmaceuticals, inc. (nasdaq: acrx), (acelrx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that its commercial partner, laboratorie aguettant ("aguettant"), has launched dzuveo® (sufentanil sublingual tablet, 30 mcg), which is branded as dsuvia® in the u.s., across europe.
ACRX Ratings Summary
ACRX Quant Ranking